YU2000A - Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens - Google Patents
Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agensInfo
- Publication number
- YU2000A YU2000A YU2000A YU2000A YU2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A YU 2000 A YU2000 A YU 2000A
- Authority
- YU
- Yugoslavia
- Prior art keywords
- atorvastatin
- combinations
- combination therapy
- antihypertensive agent
- hyperlipidemia
- Prior art date
Links
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 title abstract 3
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 title abstract 3
- 229940030600 antihypertensive agent Drugs 0.000 title abstract 3
- 239000002220 antihypertensive agent Substances 0.000 title abstract 3
- 229960005370 atorvastatin Drugs 0.000 title abstract 3
- 238000002648 combination therapy Methods 0.000 title 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 2
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 2
- 206010020772 Hypertension Diseases 0.000 abstract 2
- 230000000747 cardiac effect Effects 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 208000024891 symptom Diseases 0.000 abstract 2
- 239000011885 synergistic combination Substances 0.000 abstract 2
- 239000000654 additive Substances 0.000 abstract 1
- 230000000996 additive effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Iron Core Of Rotating Electric Machines (AREA)
- Pyrrole Compounds (AREA)
Abstract
Ovaj pronalazak se odnosi na farmaceutske kombinacije atorvastatina ili njegove farmaceutski prihvatljive soli i antihipertenzivnih agenasa. Ovaj pronalazak se, takodje, odnosi na aditive i sinergističke kombinacije atorvastatina ili njegove farmaceutski prihvatljive soli.[This invention relates to pharmaceutical combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents, kits containing such combinations and methods of using such combinations to treat subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and to treat subjects presenting with symptoms of cardiac risk, including humans. This invention also relates to additive and synergistic combinations of atorvastatin or a pharmaceutically acceptable salt thereof and antihypertensive agents whereby those synergistic combinations are useful in treating subjects suffering from angina pectoris, atherosclerosis, combined hypertension and hyperlipidemia and those subjects presenting with symptoms of cardiac risk, including humans.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5727697P | 1997-08-29 | 1997-08-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| YU2000A true YU2000A (sh) | 2002-12-10 |
Family
ID=22009602
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| YU2000A YU2000A (sh) | 1997-08-29 | 1998-08-11 | Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens |
Country Status (41)
| Country | Link |
|---|---|
| US (2) | US20020099046A1 (sh) |
| EP (1) | EP1009400B1 (sh) |
| JP (2) | JP2001514223A (sh) |
| KR (3) | KR20040106591A (sh) |
| CN (3) | CN1473567A (sh) |
| AP (1) | AP1191A (sh) |
| AR (1) | AR016399A1 (sh) |
| AT (1) | ATE285767T1 (sh) |
| AU (1) | AU740424B2 (sh) |
| BG (1) | BG64724B1 (sh) |
| BR (1) | BR9811556A (sh) |
| CA (1) | CA2296723A1 (sh) |
| CO (1) | CO4970724A1 (sh) |
| DE (1) | DE69828413T2 (sh) |
| DZ (1) | DZ2595A1 (sh) |
| EA (1) | EA200000012A1 (sh) |
| EG (1) | EG24678A (sh) |
| ES (1) | ES2234134T3 (sh) |
| GT (1) | GT199800126A (sh) |
| HR (1) | HRP980474A2 (sh) |
| HU (1) | HUP0004318A3 (sh) |
| ID (1) | ID24118A (sh) |
| IL (2) | IL133962A0 (sh) |
| IS (1) | IS5341A (sh) |
| MA (1) | MA26536A1 (sh) |
| MY (1) | MY121008A (sh) |
| NO (1) | NO323987B1 (sh) |
| NZ (2) | NZ502280A (sh) |
| OA (1) | OA11291A (sh) |
| PA (1) | PA8457901A1 (sh) |
| PE (1) | PE107099A1 (sh) |
| PL (1) | PL339091A1 (sh) |
| PT (1) | PT1009400E (sh) |
| SA (1) | SA98190603B1 (sh) |
| SK (1) | SK1432000A3 (sh) |
| TN (1) | TNSN98155A1 (sh) |
| TR (1) | TR200000563T2 (sh) |
| UY (1) | UY25155A1 (sh) |
| WO (1) | WO1999011260A1 (sh) |
| YU (1) | YU2000A (sh) |
| ZA (1) | ZA987839B (sh) |
Families Citing this family (76)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0656786B2 (en) | 1992-05-19 | 2014-04-23 | Novogen Research Pty Ltd | Use of isoflavone phyto-oestrogen extracts of soy or clover |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| AUPO203996A0 (en) | 1996-08-30 | 1996-09-26 | Novogen Research Pty Ltd | Therapeutic uses |
| GT199800127A (es) * | 1997-08-29 | 2000-02-01 | Combinaciones terapeuticas. | |
| KR20010041916A (ko) * | 1998-03-17 | 2001-05-25 | 로즈 암스트롱, 크리스틴 에이. 트러트웨인 | 스타틴-매트릭스 메탈로프로테이나제 저해제 복합제제 |
| EP1340508A1 (en) | 1998-12-23 | 2003-09-03 | G.D. Searle LLC. | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| AU2007200367B2 (en) * | 1999-02-06 | 2010-04-08 | Astrazeneca Ab | Use of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors for the manufacture of a medicament for the treatment of diabetic neuropathy |
| GB0001662D0 (en) | 1999-02-06 | 2000-03-15 | Zeneca Ltd | Pharmaceutical compositions |
| JP4870888B2 (ja) | 1999-08-30 | 2012-02-08 | サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 心血管の病態の予防におけるレニン−アンギオテンシン系阻害剤の使用 |
| AUPQ266199A0 (en) | 1999-09-06 | 1999-09-30 | Novogen Research Pty Ltd | Compositions and therapeutic methods involving isoflavones and analogues thereof |
| DE19944803A1 (de) * | 1999-09-20 | 2001-03-29 | Bayer Ag | Kombination von Dihydropyridinverbindungen und HMG-CoA-Reduktase-Inhibitoren und ihre Verwendung in Arzneimitteln |
| ATE309807T1 (de) | 1999-09-24 | 2005-12-15 | Vasogen Ireland Ltd | Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält |
| FR2803525B1 (fr) * | 2000-01-06 | 2002-05-03 | Sod Conseils Rech Applic | Inhibiteur de la transduction des signaux des proteines g heterotrimeriques associe a un agent anti-hypertenseur dans le traitement de l'hypertension arterielle |
| AR030414A1 (es) * | 2000-04-03 | 2003-08-20 | Astrazeneca Ab | Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos |
| GB2361185A (en) | 2000-04-10 | 2001-10-17 | Nicholas J Wald | Pharmaceutical formulation for the prevention of cardiovascular disease |
| SE0002354D0 (sv) * | 2000-06-22 | 2000-06-22 | Astrazeneca Ab | New formulation |
| DE60135560D1 (de) | 2000-07-19 | 2008-10-09 | Novartis Ag | Valsartan salze |
| CA2420844A1 (en) * | 2000-08-30 | 2003-02-28 | Sankyo Company, Limited | Medicinal compositions for preventing or treating heart failure |
| US7018649B2 (en) * | 2000-10-23 | 2006-03-28 | Euro-Celtique, S.A. | Felodipine transdermal device and methods |
| US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
| US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
| AUPR255401A0 (en) * | 2001-01-16 | 2001-02-08 | Novogen Research Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
| KR100820983B1 (ko) | 2001-01-26 | 2008-04-10 | 쉐링 코포레이션 | 치환된 아제티딘온 화합물을 포함하는 약제학적 조성물 |
| US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
| MEP27808A (en) | 2001-01-26 | 2010-10-10 | Schering Corp | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications |
| AUPR363301A0 (en) | 2001-03-08 | 2001-04-05 | Novogen Research Pty Ltd | Dimeric isoflavones |
| AP2004002951A0 (en) * | 2001-07-19 | 2004-03-31 | Pharmacia Corp | "Combination of Eplerenone and an HMG CoA Reductase Inhibitor". |
| PE20030324A1 (es) * | 2001-07-31 | 2003-04-03 | Warner Lambert Co | Composiciones farmaceuticas de amlodipina y atorvastatina |
| US6852737B2 (en) | 2001-08-06 | 2005-02-08 | Recordati Ireland Limited | Crude and crystalline forms of lercanidipine hydrochloride |
| US7053080B2 (en) | 2001-09-21 | 2006-05-30 | Schering Corporation | Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors |
| US7056906B2 (en) | 2001-09-21 | 2006-06-06 | Schering Corporation | Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women |
| DK1429756T3 (da) | 2001-09-21 | 2007-03-19 | Schering Corp | Behandling af xanthoma med azetidinonderivater som sterolabsorptionsinhibitorer |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| CA2471639A1 (en) | 2002-01-17 | 2003-07-31 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| CA2490636A1 (en) * | 2002-06-20 | 2003-12-31 | The Governors Of The University Of Alberta | Dichloroacetate in combination with cardioprotective or hemodynamic drugs |
| CA2492060C (en) * | 2002-06-27 | 2011-11-01 | Sb Pharmco Puerto Rico Inc. | Carvedilol phosphate salts and/or solvates thereof, corresponding compositions, and/or methods of treatment |
| EP1539140A4 (en) * | 2002-06-27 | 2005-12-07 | Sb Pharmco Inc | CARVEDILOLHYDOBROMID |
| US7071210B2 (en) * | 2002-07-02 | 2006-07-04 | Pfizer Inc. | CETP inhibitors in combination with antihypertensive agents and uses thereof |
| US20040053842A1 (en) * | 2002-07-02 | 2004-03-18 | Pfizer Inc. | Methods of treatment with CETP inhibitors and antihypertensive agents |
| GB0221579D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Combinations of atorvastatin and, adrenergic receptor antagonists |
| EP1553941A1 (en) * | 2002-10-16 | 2005-07-20 | Recordati Ireland Limited | Lisinopril/lercanidipine combination therapy |
| AU2003291719A1 (en) | 2002-11-06 | 2004-06-03 | Schering Corporation | Cholesterol absorptions inhibitors for the treatment of autoimmune disorders |
| WO2004081002A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| US7459442B2 (en) | 2003-03-07 | 2008-12-02 | Schering Corporation | Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof |
| WO2004081004A1 (en) | 2003-03-07 | 2004-09-23 | Schering Corporation | Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia |
| CN1756756A (zh) | 2003-03-07 | 2006-04-05 | 先灵公司 | 取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途 |
| GB0322552D0 (en) | 2003-09-26 | 2003-10-29 | Astrazeneca Uk Ltd | Therapeutic treatment |
| WO2005051383A1 (en) * | 2003-11-25 | 2005-06-09 | Sb Pharmco Puerto Rico Inc. | Carvedilol salts, corresponding compositions, methods of delivery and/or treatment |
| JP2007512350A (ja) * | 2003-11-25 | 2007-05-17 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | カルベジロール組成物の治療および送達方法 |
| EP1691789B1 (en) * | 2003-11-25 | 2017-12-20 | SmithKline Beecham (Cork) Limited | Carvedilol free base, salts, anhydrous forms or solvate thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods |
| KR20050092519A (ko) * | 2004-03-16 | 2005-09-22 | 화이자 인코포레이티드 | 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합 |
| EP1734958A1 (en) * | 2004-04-06 | 2006-12-27 | Merck & Co., Inc. | Methods for the treatment of hypertension |
| CA2568640C (en) | 2004-06-04 | 2011-08-09 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
| WO2006026469A2 (en) * | 2004-08-25 | 2006-03-09 | Essentialis, Inc. | Pharmaceutical formulations of potassium atp channel openers and uses thereof |
| EP1848425B1 (en) * | 2005-02-17 | 2011-08-17 | CHIESI FARMACEUTICI S.p.A. | Therapeutic combinations of manidi pine and simvastatin |
| EP2000137B1 (en) * | 2006-03-29 | 2015-10-21 | Kowa Company, Ltd. | Triglyceride-lowering agent and hyperinsulinism-ameliorating agent |
| US8642083B2 (en) * | 2006-10-30 | 2014-02-04 | Hanall Biopharma Co., Ltd. | Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors |
| EP2281557A4 (en) | 2008-04-29 | 2011-08-31 | Hanall Biopharma Co Ltd | PHARMACEUTICAL FORMULATION CONTAINING AN ANGIOTENSIN II RECEPTOR BLOCKING AGENT |
| CZ301299B6 (cs) * | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
| NZ594738A (en) * | 2009-01-23 | 2013-11-29 | Hanmi Science Co Ltd | Solid pharmaceutical composition comprising amlodipine and losartan and process for producing same |
| SI23149A (sl) * | 2009-09-21 | 2011-03-31 | Silverstone Pharma | Nove benzatinske soli ACE inhibitorjev, postopek za njihovo pripravo in njihova uporaba za zdravljenje kardiovaskularnih bolezni |
| RU2481124C1 (ru) * | 2011-10-27 | 2013-05-10 | Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" | Фармацевтическая комбинация из аторвастатина и ницерголина для профилактики или лечения нарушений мозгового кровообращения |
| CN102671198A (zh) * | 2011-12-17 | 2012-09-19 | 东莞达信生物技术有限公司 | 一种降压降脂复方药及其制备方法 |
| KR20140028971A (ko) * | 2012-08-31 | 2014-03-10 | 한미약품 주식회사 | 아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제 |
| WO2014142521A1 (ko) * | 2013-03-12 | 2014-09-18 | 주식회사 엘지생명과학 | 발사르탄 및 로수바스타틴 칼슘을 포함하는 복합 제제 및 이의 제조방법 |
| CN104173420A (zh) * | 2013-05-20 | 2014-12-03 | 广州诺氏刘生物科技有限公司 | 一种治疗急性肾衰竭的药物 |
| KR102484589B1 (ko) | 2014-10-23 | 2023-01-04 | 아레나 파마슈티칼스, 인크. | Ｐｇｉ2 수용체 관련 병태의 치료 방법 |
| RU2724338C2 (ru) * | 2015-06-30 | 2020-06-23 | Ханми Фарм. Ко., Лтд. | Фармацевтическая комплексная композиция, включающая амлодипин, лозартан и розувастатин |
| FR3040303B1 (fr) * | 2015-08-27 | 2019-04-05 | Les Laboratoires Servier Suivi Par Sabine Goudeau-Wenger | Composition pharmaceutique comprenant un inhibiteur de la hmg-coa reductase et un inhibiteur eca |
| CN105232555A (zh) * | 2015-11-19 | 2016-01-13 | 哈尔滨圣吉药业股份有限公司 | 一种替米沙坦/瑞舒伐他汀复方制剂及其制备方法 |
| AU2017274438A1 (en) * | 2016-06-02 | 2018-12-13 | Ana Pharmaceuticals, Inc. | Methods and compositions for treatment of hypercalciuria and nephrolithiasis |
| PT3573620T (pt) | 2017-01-25 | 2023-03-20 | The George Inst For Global Health | Composições para o tratamento da hipertensão |
| ES2897024T3 (es) | 2017-03-01 | 2022-02-28 | Arena Pharm Inc | Composiciones que comprenden agonistas del receptor de PGI2 y procesos para la preparación de las mismas |
| EP3826633A4 (en) * | 2018-07-26 | 2022-04-27 | The George Institute For Global Health | COMPOSITIONS FOR THE TREATMENT OF HYPERTENSION |
| CN112826937B (zh) * | 2021-03-25 | 2022-03-22 | 山东大学齐鲁医院 | 艾地苯醌与他汀类药物联用在防治动脉粥样硬化中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) * | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) * | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5447922A (en) * | 1994-08-24 | 1995-09-05 | Bristol-Myers Squibb Company | α-phosphonosulfinic squalene synthetase inhibitors |
| NZ286920A (en) * | 1995-07-03 | 1997-06-24 | Sankyo Co | Use of combination of hmg-coa reductase inhibitors and of insulin sensitizers for the prevention/treatment of arteriosclerosis or xanthoma |
| DE69636783T2 (de) * | 1995-11-02 | 2007-10-18 | Warner-Lambert Co. Llc | Verfahren und pharmazeutische zusammensetzung zur regelung der lipidkonzentration |
-
1998
- 1998-08-07 GT GT199800126A patent/GT199800126A/es unknown
- 1998-08-11 NZ NZ502280A patent/NZ502280A/xx unknown
- 1998-08-11 AU AU84589/98A patent/AU740424B2/en not_active Ceased
- 1998-08-11 NZ NZ530630A patent/NZ530630A/en unknown
- 1998-08-11 YU YU2000A patent/YU2000A/sh unknown
- 1998-08-11 CA CA002296723A patent/CA2296723A1/en not_active Abandoned
- 1998-08-11 BR BR9811556-1A patent/BR9811556A/pt not_active Application Discontinuation
- 1998-08-11 ES ES98935250T patent/ES2234134T3/es not_active Expired - Lifetime
- 1998-08-11 CN CNA031430937A patent/CN1473567A/zh active Pending
- 1998-08-11 WO PCT/IB1998/001230 patent/WO1999011260A1/en active Application Filing
- 1998-08-11 KR KR10-2004-7019432A patent/KR20040106591A/ko not_active Ceased
- 1998-08-11 IL IL13396298A patent/IL133962A0/xx not_active IP Right Cessation
- 1998-08-11 HU HU0004318A patent/HUP0004318A3/hu unknown
- 1998-08-11 PT PT98935250T patent/PT1009400E/pt unknown
- 1998-08-11 TR TR2000/00563T patent/TR200000563T2/xx unknown
- 1998-08-11 CN CNA031430929A patent/CN1473566A/zh active Pending
- 1998-08-11 SK SK143-2000A patent/SK1432000A3/sk unknown
- 1998-08-11 KR KR1020007001062A patent/KR20010022477A/ko not_active Ceased
- 1998-08-11 DE DE69828413T patent/DE69828413T2/de not_active Expired - Fee Related
- 1998-08-11 JP JP2000508363A patent/JP2001514223A/ja not_active Withdrawn
- 1998-08-11 CN CN98808463A patent/CN1268053A/zh active Pending
- 1998-08-11 KR KR10-2003-7000672A patent/KR20030015394A/ko not_active Ceased
- 1998-08-11 EA EA200000012A patent/EA200000012A1/ru unknown
- 1998-08-11 ID IDW20000196A patent/ID24118A/id unknown
- 1998-08-11 EP EP98935250A patent/EP1009400B1/en not_active Expired - Lifetime
- 1998-08-11 PL PL98339091A patent/PL339091A1/xx unknown
- 1998-08-11 AT AT98935250T patent/ATE285767T1/de not_active IP Right Cessation
- 1998-08-17 PA PA19988457901A patent/PA8457901A1/es unknown
- 1998-08-24 PE PE1998000769A patent/PE107099A1/es not_active Application Discontinuation
- 1998-08-26 DZ DZ980205A patent/DZ2595A1/xx active
- 1998-08-26 TN TNTNSN98155A patent/TNSN98155A1/fr unknown
- 1998-08-26 MA MA25228A patent/MA26536A1/fr unknown
- 1998-08-26 UY UY25155A patent/UY25155A1/es not_active Application Discontinuation
- 1998-08-27 AP APAP/P/1998/001332A patent/AP1191A/en active
- 1998-08-27 EG EG102598A patent/EG24678A/xx active
- 1998-08-27 CO CO98049139A patent/CO4970724A1/es unknown
- 1998-08-27 MY MYPI98003941A patent/MY121008A/en unknown
- 1998-08-27 AR ARP980104287A patent/AR016399A1/es unknown
- 1998-08-28 HR HR60/057,276A patent/HRP980474A2/hr not_active Application Discontinuation
- 1998-08-28 ZA ZA9807839A patent/ZA987839B/xx unknown
- 1998-09-30 SA SA98190603A patent/SA98190603B1/ar unknown
-
2000
- 2000-01-09 IL IL133962A patent/IL133962A/en unknown
- 2000-01-13 BG BG104075A patent/BG64724B1/bg unknown
- 2000-01-14 IS IS5341A patent/IS5341A/is unknown
- 2000-02-18 OA OA1200000040A patent/OA11291A/en unknown
- 2000-02-28 NO NO20000996A patent/NO323987B1/no unknown
-
2001
- 2001-10-23 US US10/045,329 patent/US20020099046A1/en not_active Abandoned
-
2003
- 2003-05-19 US US10/442,285 patent/US20030199492A1/en not_active Abandoned
-
2004
- 2004-07-22 JP JP2004214382A patent/JP2005041875A/ja not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| YU2000A (sh) | Farmaceutski preparat koji sadrži atorvastatin i antihipertenzivni agens | |
| MY123993A (en) | Therapeutic combinations | |
| CA2296726A1 (en) | Combination therapy | |
| AU6257798A (en) | Treatment of arrhythmias via inhibition of a multifunctional calcium/calmodulin-dependent protein kinase | |
| PT1014961E (pt) | Tratamento da cefaleia de enxaqueca utilizando metoclopramida e um nsaid | |
| EA200300155A1 (ru) | Терапевтическая комбинация ингибитора сетр и аторвастатина | |
| TR200101470T2 (tr) | Farmasötik bileşim terkipleri. | |
| IL132853A0 (en) | Combination therapy for modulating the human sexual response | |
| ECSP982647A (es) | Terapia de combinacion | |
| ECSP982645A (es) | Terapia de combinacion | |
| ECSP982646A (es) | Combinaciones terapeuticas | |
| AU6920398A (en) | Medicament for preventive and therapeutic treatment of inflammatory diseas es | |
| UY27510A1 (es) | Terapia de combinación |